TOBI Podhaler for treating chronic Pseudomonas aeruginosa infection in cystic fibrosis patients]

TOBI Podhaler is the first dry powder formulation of tobramycin for inhaled therapy of chronic Pseudomonas aeruginosa infection in cystic fibrosis patients from the age of 6 years. Clinical studies show a safety and efficacy profile comparable to tobramycin inhaled solution (TOBI). The short administration time and the convenient use of the system may significantly decrease the treatment burden. This paper gives a short review of the clinical studies and some practical information.